Generic Name and Formulations:
Nusinersen 12mg/5mL; soln for intrathecal inj; preservative-free.
Indications for SPINRAZA:
Spinal muscular atrophy.
Adults and Children:
Consider sedation and ultrasound or other imaging techniques as guidance. Remove 5mL of cerebrospinal fluid prior to inj. Give as intrathecal bolus inj over 1–3 mins. 12mg (5mL) per dose. Initially: give 3 loading doses at 14-day intervals then give 4th loading dose 30 days after. Maintenance: give dose once every 4 months thereafter.
Do not administer in areas of infected or inflamed skin. Increased risk of bleeding complications. Perform platelet count, prothrombin time, aPTT, quantitative spot urine protein testing at baseline, prior to each dose, and as clinically needed; consider repeat testing if urine protein >0.2g/L. Pregnancy. Nursing mothers.
Lower/upper respiratory infection, constipation, teething; thrombocytopenia, coagulation abnormalities, renal toxicity.
Neurology Advisor Articles
- Self-Controlled Electric Stimulation a Good Alternative to Drug Therapy for Migraine
- Elevated Copeptin Levels in Acute Headache May Signify More Serious Etiology
- New Sleep Apnea Clinical Practice Guidelines
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- Neural Targeting Spinal Cord Stimulation Superior for Axial Low Back Pain
- DHA Supplementation Has No Impact on IQ in Offspring
- Safinamide Approved as Adjunctive Therapy for Parkinson's
- International League Against Epilepsy Updates Epilepsy Classification System
- Depression, Schizophrenia Identified With Objective Blood Biomarker
- Autoimmune Disease Hospitalization Linked to Future Dementia Risk